Neurocrine Biosciences Inc
(STU:NB3)
€
149.05
-0.85 (-0.57%)
Market Cap: 15.09 Bil
Enterprise Value: 14.29 Bil
PE Ratio: 26.33
PB Ratio: 5.04
GF Score: 93/100 Neurocrine Biosciences Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022 / 05:35PM GMT
Release Date Price:
€120.88
(+0.72%)
Joshua Elliott Schimmer
Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
All right. Welcome, everyone. This is Josh Schimmer from the Evercore ISI Biotech team. Please introduce our next company, Neurocrine Biosciences, Chief Executive Officer, Kevin Gorman; and Chief Financial Officer, Matt Abernethy. Gentlemen, welcome. Great to see you again. Thanks for your time.
Questions & Answers
Joshua Elliott Schimmer
Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
INGREZZA, powering through COVID, even though it feels like COVID is still impacting the psychiatry practice. Maybe give us a sense of what's worked so well as part of this recovery process or the segment of medicine that still seems very well known?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Yes, Josh, it's a good question. And good to see you, too. And thank you very much to you and to Evercore for the opportunity to speak here. Before I get going,
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot